Biomerica, Inc.BMRANASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-8.96%
↓ 613% below average
Average (39q)
1.75%
Historical baseline
Range
High:40.62%
Low:-35.00%
CAGR
-2.0%
Modest growth trend
| Period | Value |
|---|---|
| Q4 2025 | -8.96% |
| Q3 2025 | -15.87% |
| Q2 2025 | 16.13% |
| Q1 2025 | -15.56% |
| Q4 2024 | -13.47% |
| Q3 2024 | 12.08% |
| Q2 2024 | -22.74% |
| Q1 2024 | -16.75% |
| Q4 2023 | -12.71% |
| Q3 2023 | 27.96% |
| Q2 2023 | -5.91% |
| Q1 2023 | -15.13% |
| Q4 2022 | 27.90% |
| Q3 2022 | 21.59% |
| Q2 2022 | -35.00% |
| Q1 2022 | -26.11% |
| Q4 2021 | 40.62% |
| Q3 2021 | -24.96% |
| Q2 2021 | 4.08% |
| Q1 2021 | -8.65% |
| Q4 2020 | -13.34% |
| Q3 2020 | 7.54% |
| Q2 2020 | 39.79% |
| Q1 2020 | 16.90% |
| Q4 2019 | 9.28% |
| Q3 2019 | -9.38% |
| Q2 2019 | -17.76% |
| Q1 2019 | 30.33% |
| Q4 2018 | -2.65% |
| Q3 2018 | -19.02% |
| Q2 2018 | 36.83% |
| Q1 2018 | 29.78% |
| Q4 2017 | -5.60% |
| Q3 2017 | -17.24% |
| Q2 2017 | 35.83% |
| Q1 2017 | -14.70% |
| Q4 2016 | 34.21% |
| Q3 2016 | 8.40% |
| Q2 2016 | 11.65% |
| Q1 2016 | -19.52% |